Physician profile
Andrew Scrogin
NPI 1003817594
$512.14
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $60.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $115.82 | 2019 | |
| Amneal Pharmaceuticals LLC | $66.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.25 | 2019 | |
| Novo Nordisk INC | $46.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.30 | 2019-2020 | |
| Abbvie INC. | $38.07 | 2019-2020 | |
| Corcept Therapeutics | $24.98 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.62 | 2020 | |
| Abbott Laboratories | $22.56 | 2019 | |
| Gilead Sciences, INC. | $20.68 | 2019 | |
| Cranial Technologies, INC | $14.55 | 2019 | |
| Medtronic Minimed, INC. | $13.15 | 2020 | |
| Ibsa Pharma INC. | $12.58 | 2019 | |
| Alexion Pharmaceuticals, INC. | $10.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Scrogin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.